OPEN END TURBO PUT WARRANT - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 07:55:53 2024-07-02 EDT | ||
| 7.59 EUR | +1.47% |
|
| Current month | -3.11% | ||
| 1 month | -55.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-02 | 7.59 | +1.47% |
| 24-07-01 | 7.48 | -3.11% |
| 24-06-28 | 7.72 | -8.31% |
| 24-06-27 | 8.42 | -5.18% |
| 24-06-26 | 8.88 | +3.74% |
Real-time Boerse Frankfurt Warrants
Last update July 02, 2024 at 07:55 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| WKN | UM2B5E |
| ISIN | DE000UM2B5E5 |
| Date issued | 2024-02-05 |
| Strike | 993.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 30.93 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.13 € |
|---|---|
| Lowest since issue | 7.13 € |
| Spread | 0.31 € |
| Spread % | 3.49% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
914.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.97%
- Stock Market
- Certificates
- Certificat
